Business Wire

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

7.9.2023 10:00:00 EEST | Business Wire | Press release

Share

Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/

CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.

Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.

CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.

Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.

CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.

Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.

Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

About Cerba HealthCare

Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.

Cerba HealthCare, enlightening health.

Additional information is available at www.cerbahealthcare.com

About Cerba Research

We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.​

We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.​

Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.

For more information visit www.cerbaresearch.com

About CIRION

CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).

Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts:

Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com

CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade20.2.2026 13:32:00 EET | Press release

Telekom Srbija Group today announced its Platinum Sponsorship of EXPO 2027 Belgrade, marking a major milestone in the company’s continued leadership in digital innovation and infrastructure across the region. As a Platinum Sponsor, Telekom Srbija will play a central role in delivering the digital backbone of EXPO 2027, powering connectivity and enabling the state-of-the-art technological infrastructure that will support one of the largest international events ever hosted in Serbia. EXPO 2027 represents a defining moment for Belgrade, Serbia, and the wider region. For Telekom Srbija, the partnership is both a strategic commitment and a landmark opportunity to demonstrate the full strength of its technological ecosystem on a global stage. Telekom Srbija will also host its own pavilion at EXPO 2027, creating an immersive space to showcase its technologies, innovation platforms and future-facing solutions. Vladimir Lučić, CEO of Telekom Srbija, stated: “EXPO 2027 is a milestone moment for

Axelspace Secures Japan Ministry of Defense Satellite Constellation Project20.2.2026 13:01:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that, for the purpose of carrying out the Ministry of Defense’s satellite constellation project, it has entered into a contract with Tri-Sat Constellation Co., Ltd. and Mitsui Bussan Aerospace Co., Ltd. for acquisition of optical imagery data. Tri-Sat Constellation Co., Ltd. is a special purpose company (SPC) established by Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, and Mitsui & Co., Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220758297/en/ An imagery of satellite constellation © the Ministry of Defense The Ministry of Defense’s satellite constellation project was awarded to a consortium comprising Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, Mitsui & Co., Ltd., Synspective Inc., Institute for Q-shu Pioneers of Space

Sai Life Sciences to Recruit 700+ Professionals in FY2720.2.2026 11:09:00 EET | Press release

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220711675/en/ Integrated R&D Campus, Sai Life Sciences, Hyderabad, India The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others. A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally,

Balmain Beauty Introduces Destin de Balmain: A New Prestige Fragrance20.2.2026 09:30:00 EET | Press release

Balmain Beauty unveils Destin de Balmain, its debut prestige fragrance. The new feminine fragrance is a bold, floral fruity eau de parfum that captures the unstoppable energy of the Balmain woman: independent, youthful, and unapologetic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219851364/en/ Destin de Balmain (Photo Credit: Balmain Beauty) THE STORY: LIVE YOUR DESTINY Destin de Balmain is destiny you hold in your hands, a journey of optimism and infinite possibilities. The refillable fragrance unites those who express themselves without rules or expectations. Inspired by the Parisian House’s savoir-faire and modern pulse, the daring fragrance celebrates choosing your path and living your destiny. “Destin de Balmain features a joyful, optimistic spark of ripe strawberry,” said Quentin Bisch, Perfumer. “The fruit’s juicy vivacity brings bright, elevated sweetness to the composition. Notes of peony further convey the f

SOLUM and EWQ Announce Strategic Partnership Expansion at EuroShop to Advance Integrated In-Store Digital Communication20.2.2026 09:00:00 EET | Press release

SOLUM (KOSPI: 248070), a global retail solutions provider, and EWQ, a leading retail infrastructure innovator, have announced the expansion of their strategic partnership to accelerate integrated in-store digital communication. Building on their existing collaboration, the two companies will deepen technology integration and commercial cooperation to deliver a unified platform connecting Electronic Shelf Labels (ESL), large-format E-Paper displays, and digital signage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219422813/en/ ScanToPair enables seamless pairing of products and digital signage through simple barcode scanning, automatically synchronizing product and pricing information. (Image: SOLUM) A central focus of the expanded partnership is the integration of EWQ’s ScanToPair solution with SOLUM’s Newton ESL and digital signage. ScanToPair enables seamless pairing of products and digital signage through simple bar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye